Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
Theriva Biologics, Inc., a Nevada corporation, filed this Current Report on Form 8-K on March 12, 2026. The filing serves to announce the issuance of a press release containing financial information for the fiscal year ended December 31, 2025. The company is listed on the NYSE American under the symbol TOVX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document solely references the existence of the fiscal year 2025 results in the attached press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The text does not provide specific management commentary, forward-looking guidance, or a detailed discussion of risks and contingencies beyond this legal disclaimer.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 12, 2026) for specific fiscal year 2025 financial results.
- Verify the company's liquidity position and cash runway as detailed in the full press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Check for any subsequent filings that may incorporate the press release data by reference.